Latest News and Press Releases

– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected...

– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Kiniksa to receive $22 million upfront; eligible to receive...

HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022,...

- ARCALYST® full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 –- KPL-404 Phase 2 trial in rheumatoid arthritis...

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday,...

HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate...

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual...

- Q3 2021 ARCALYST® (rilonacept) net revenue of $12.1 million -- ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval -- Data from Phase 3 trial of mavrilimumab in...

HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at...

HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...